Latest Immunosuppressants Stories
Primary Efficacy Analysis Demonstrates Clinical Equivalence THOUSAND OAKS, Calif., Feb.
-33% rate of DAS28-CRP remission or low disease activity reported in Phase 2a cohort- MONROVIA, Calif., Jan. 29, 2015 /PRNewswire/ -- Xencor, Inc.
US Submission Designed to Support Conversion From Accelerated to Full FDA Approval and Expansion of Current Approved Indication THOUSAND OAKS, Calif.
LONDON, January 22, 2015 /PRNewswire/ -- Report Details Treating Crohn's disease and ulcerative colitis - how to find R&D trends, opportunities and revenue
- Phase III data demonstrated Cosentyx resulted in clear or almost clear skin in the majority of patients with moderate-to-severe plaque psoriasis EAST HANOVER, N.J., Jan.
-- First biosimilar from Samsung Bioepis to advance to EMA regulatory review -- INCHEON, South Korea, Jan.
HORSHOLM, Denmark, Jan. 14, 2015 /PRNewswire/ -- Veloxis Pharmaceuticals A/S (OMX: VELO) (Veloxis) today confirmed that the U.S.
HORSHOLM, Denmark, Jan. 13, 2015 /PRNewswire/ -- Veloxis Pharmaceuticals A/S (OMX: VELO) (Veloxis) today confirmed that it has received notice from the U.S.
HORSHOLM, Denmark, Dec. 19, 2014 /PRNewswire/ -- Veloxis Pharmaceuticals A/S (OMX: VELO) (Veloxis) today issued the following statement regarding an order issued by the U.S.
ReportsandReports.com adds latest reports on Adalimumab Industry for Global and China Markets to its store. DALLAS, Dec.
- An armed gangster.